So if it is about to be reinstated to official quotation, where are the details regarding the Board's review of the data for phase 2 which was the justification for the trading halt?
Ann: Antisense Therapeutics - Underwriting of Listed Options, page-17
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $85.01M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $103.7K | 1.237M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 204084 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 280000 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |